← All trials
NCT06409364
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2024
- Primary completion
- Jul 31, 2029
- Completion date
- Jul 31, 2030
- First posted
- May 10, 2024
- Last posted
- Aug 16, 2024
- Enrollment
- 524
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- University of New South WalesOfficial
- Townsville University HospitalOfficial
- Royal Hobart Hospital, TAS, AustraliaOfficial
- Monash UniversityOfficial
- Griffith UniversityOfficial
- University of SydneyOfficial
- University of SydneyOfficial
- University of SydneyOfficial
- University of AucklandOfficial
- Prince of Wales HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.